Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda to sell Techpool to Chinese JV partners
The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. (Shanghai Pharma SSE
The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. (Shanghai Pharma SSE
The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. Sanofi development global head and
The patents, among other aspects, broadly cover compositions of matter of the inflammation-targeting microfiber materials with embedded molecules of interest. The platform is being evaluated for use across
The clinical equivalence study is being conducted in 24 healthy subjects in a double-blind, randomised, parallel group protocol to evaluate the interchangeability between Q-Octreotide and the reference product,
Hyperkalemia is a serious condition characterized by high levels of potassium in the blood (greater than 5.0 mEq/L). The risk of hyperkalemia increases significantly for patients with chronic
The newly established Seattle-based company's goal is to support GC Pharma's vaccine development activities. GC Pharma builds a strategic collaboration and partnership with global health organizations IDRI (Infectious
This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. Ipsen chief commercial officer and
Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. Treatment with LYRICA at
The agreement is a strategic step with the leading contract manufacturer in India to extend the opportunities offered by LPLDL into India and Southern Asia. Under the terms
This phase 2a multi-centre and multi-country clinical trial (CDKO-125A-010) in sorafenib-refractory or -intolerable patients with unresectable or metastatic hepatocellular carcinoma (HCC) is being conducted in Greece, Italy and